Abstract
Latin America has been severely affected by the COVID-19 pandemic. The COVID-19 burden in rural settings in Latin America is unclear. We performed a cross-sectional, population-based, random-selection SARS-CoV-2 serological study during March 2021 in the rural population of San Martin region, northern Peru. The study enrolled 563 persons from 288 houses across 10 provinces, reaching 0.19% of the total rural population of San Martin. Screening for SARS-CoV-2 IgG antibodies was done using a chemiluminescence immunoassay (CLIA) and reactive sera were confirmed using a SARS-CoV-2 surrogate virus neutralization test (sVNT). Validation using pre-pandemic sera from two regions of Peru showed false-positive results in the CLIA (23/84 sera; 27%), but not in the sVNT, highlighting the pitfalls of SARS-CoV-2 antibody testing in tropical regions and the high specificity of the two-step testing algorithm. An overall 59.0% seroprevalence (95% CI: 55-63%) corroborated intense SARS-CoV-2 spread in San Martin. Seroprevalence rates between the 10 provinces varied from 41.3-74.0% (95% CI: 30-84). Higher seroprevalence was neither associated with population size, population density, surface area, mean altitude or poverty index in spearman correlations. Seroprevalence and reported incidence diverged substantially between provinces, suggesting regional biases of COVID-19 surveillance data. Potentially, limited healthcare access due to environmental, geographic, economic, and cultural factors, might lead to undetected infections in rural populations. Additionally, test avoidance to evade mandatory quarantine might affect rural regions more than urban regions. Serologic diagnostics should be pursued in resource-limited settings to inform country-level surveillance, vaccination strategies and support control measures for COVID-19.
Importance Latin America is a global hotspot of the COVID-19 pandemic. Serological studies in Latin America have been mostly performed in urban settings. Rural populations comprise 20% of the total Latin American population. Nevertheless, information of COVID-19 spread and transmission in rural settings is scarce. Using a representative population-based seroprevalence study, we detected a high seroprevalence in rural populations in San Martin, northern Peru in 2021, reaching 41 to 74 %. However, seroprevalence and reported incidence diverged substantially between regions, suggesting either limited healthcare access or test avoidance due to mandatory quarantine. Our results suggest that rural populations are highly affected by SARS-CoV-2 even though they are socio-demographically distinct from urban populations, and that highly specific serological diagnostics should be performed in resource-limited settings to support public-health strategies of COVID-19 surveillance and control.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Deutsche Gesellschaft fuer Internationale Zusammenarbeit (GIZ) GmbH contract number 88114104.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
institutional ethics committee Via Libre; number 6532-2021a gave ethical aproval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
